Ideaya’s IDE397 monotherapy data bode well for combo strategies, says Stifel

Stifel tells investors in a research note that Ideaya’s IDE397 monotherapy data bode well for ongoing combination strategies, especially as toxicity looks clean at this dose. The firm made no change to its Buy rating and $63 price target on Ideaya shares, and says the IDE397 data show a good disease control rate along with two strong responses and a handful of additional responses that are just below the 30% cutoff.